Please use this identifier to cite or link to this item:
Title: De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition
Author: Tarrado Castellarnau, Míriam
Atauri Carulla, Ramón de
Tarragó Celada, Josep
Perarnau, Jordi
Yuneva, Mariia
Thomson, Timothy M.
Cascante i Serratosa, Marta
Keywords: Càncer
Transducció de senyal cel·lular
Cellular signal transduction
Issue Date: 4-Oct-2017
Publisher: EMBO Press
Abstract: Cyclin‐dependent kinases (CDK) are rational cancer therapeutic targets fraught with the development of acquired resistance by tumor cells. Through metabolic and transcriptomic analyses, we show that the inhibition of CDK4/6 leads to a metabolic reprogramming associated with gene networks orchestrated by the MYC transcription factor. Upon inhibition of CDK4/6, an accumulation of MYC protein ensues which explains an increased glutamine metabolism, activation of the mTOR pathway and blunting of HIF‐1α‐mediated responses to hypoxia. These MYC‐driven adaptations to CDK4/6 inhibition render cancer cells highly sensitive to inhibitors of MYC, glutaminase or mTOR and to hypoxia, demonstrating that metabolic adaptations to antiproliferative drugs unveil new vulnerabilities that can be exploited to overcome acquired drug tolerance and resistance by cancer cells.
Note: Reproducció del document publicat a:
It is part of: Molecular Systems Biology, 2017, vol. 13, num. 10, p. 940
Related resource:
ISSN: 1744-4292
Appears in Collections:Articles publicats en revistes (Bioquímica i Biomedicina Molecular)

Files in This Item:
File Description SizeFormat 
673713.pdf3.26 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons